Ye Xinyun, Wei Wenjin, Zhang Zhengyu, He Chunming, Yang Ruijin, Zhang Jinshi, Wu Zhiwu, Huang Qianliang, Jiang Qiuhua
Department of Neurosurgery, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi 341000, China.
Oncotarget. 2017 Apr 18;8(16):26394-26403. doi: 10.18632/oncotarget.14445.
The sensitivity and specificity of microRNAs (miRNAs) for diagnosing glioma are controversial. We therefore performed a meta-analysis to systematically identify glioma-associated miRNAs. We initially screened five miRNA microarray datasets to evaluate the differential expression of miRNAs between glioma and normal tissues. We next compared the expression of the miRNAs in different organs and tissues to assess the sensitivity and specificity of the differentially expressed miRNAs in the diagnosis of glioma. Finally, pathway analysis was performed using GeneGO. We identified 27 candidate miRNAs associated with glioma initiation, progression, and patient prognosis. Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma. Ten signaling pathways showed the strongest association with glioma development and progression: the p53 pathway feedback loops 2, Interleukin signaling pathway, Toll receptor signaling pathway, Parkinson's disease, Notch signaling pathway, Cadherin signaling pathway, Apoptosis signaling pathway, VEGF signaling pathway, Alzheimer disease-amyloid secretase pathway, and the FGF signaling pathway. Our results indicate that the integration of miRNA, gene, and protein expression data can yield valuable biomarkers for glioma diagnosis and treatment. Indeed, six of the miRNAs identified in this study may be useful diagnostic and prognostic biomarkers in glioma.
微小RNA(miRNA)用于诊断神经胶质瘤的敏感性和特异性存在争议。因此,我们进行了一项荟萃分析,以系统地鉴定与神经胶质瘤相关的miRNA。我们首先筛选了五个miRNA微阵列数据集,以评估神经胶质瘤组织与正常组织之间miRNA的差异表达。接下来,我们比较了miRNA在不同器官和组织中的表达,以评估差异表达的miRNA在神经胶质瘤诊断中的敏感性和特异性。最后,使用GeneGO进行通路分析。我们鉴定出27个与神经胶质瘤起始、进展及患者预后相关的候选miRNA。敏感性和特异性分析表明,miR-15a、miR-16、miR-21、miR-23a和miR-9在神经胶质瘤中上调,而miR-124在神经胶质瘤中下调。十条信号通路与神经胶质瘤的发生和进展关联最为密切:p53通路反馈环2、白细胞介素信号通路、Toll受体信号通路、帕金森病、Notch信号通路、钙黏蛋白信号通路、凋亡信号通路、血管内皮生长因子(VEGF)信号通路、阿尔茨海默病-淀粉样前体蛋白切割酶通路和成纤维细胞生长因子(FGF)信号通路。我们的结果表明,整合miRNA、基因和蛋白质表达数据可为神经胶质瘤的诊断和治疗提供有价值的生物标志物。事实上,本研究中鉴定出的六个miRNA可能是神经胶质瘤中有用的诊断和预后生物标志物。